Recap of recent events. Thank you Flipper for starting the list. I have included a few additional items. (Emphasis mine)
"A Memphis biotech firm will add up to 80 jobs after a $9.47 million expansion of its offices and clean room...
Cognate BioServices Inc.’s permit filed with the city-county Department of Construction Code Enforcement shows 32,500 square feet will be added at 4600 E. Shelby Drive...
Plans call for completing the expansion early next year." - The Commercial Appeal article, 7/17/2015 *(final permit approval on 9/24/2015)
"NW Bio confirms phase III trial of DCVax®-L for GBM brain cancer is ongoing, patients in trial continuing to be treated per protocol, including in Germany...
Over 300 patients have been recruited for the trial...
Yes, the 300 patients are actually enrolled and being treated in the trial." - NW BIO, Form 8K, 8/25/2015
"The company has confirmed that the suspension related simply to the recruitment of new patients and was a temporary measure while regulatory information was submitted, in line with clinical protocols. The trial is continuing and we see nothing untoward in this development." - Woodford Management: Mitchell Fraser-Jones, Head of Investment Communications, 9/14/2015
"No, there is no new change or delay in the Phase 3 trial. In all of our public presentations all year long, we have stated that we anticipated finishing the recruitment this fall" - NW BIO, Form 8K, 10/8/2015
"NW Bio is not aware of any fundamental reason for the substantial decline in the price of the Company's stock" - NW BIO PR, 10/19/2015
"we have explained our attraction to the long-term potential of Northwest Biotherapeutics elsewhere on this website – nothing has changed in this regard. It would be inappropriate for us to comment further at the moment." - Woodford Management: Mitchell Fraser-Jones, Head of Investment Communications, 10/19/2015
"NW Bio has reported encouraging interim clinical data from both its DCVax-L and DCVax-Direct clinical programs, both last spring and recently, with patient survival exceeding expectations...we look forward to moving these clinical programs ahead vigorously" - Linda Powers, 10/21/2015
"Detailed negotiations are now underway to build on a contract (>£2M per annum) for the CTU to serve as a manufacturing hub for the production of DCVax-L and its broader use at multiple other facilities in UK and other European Centres." - Experimental Cancer Medicine Centre, 10/28/2015
"We plan to continue adding sites to the trial, because the same institutional approvals, contract negotiations, personnel training and logistics arrangements that are needed for the trial also serve to prepare the sites for commercialization." - NW BIO, Form S-3, 11/13/2015
